TABLE 5.
Quality, risk of bias, funding & conflicts of interest (COI) assessment of cohort studies
| Author, year | CEBM level | Selection | Comparability | Outcome | Follow-up | Funding | COI | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposed cohort | Non-exposed cohort | Ascertainment of exposure | Outcome at start | Cohorts comparable | Assessment independent | Long enough | All accounted | ||||
| Friedman, 200823 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | Non-industry | None |
| Bozdemir, 201124 | 3 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | Non-industry | None |
| Di Girolamo, 201425 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | Not specified | None |
| ElBadawey, 201410 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | Non-industry | None |
| Koskinen, 202113 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | Non-industry | None |
| Koskinen, 201726 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | Non-industry | None |
| Koskinen, 201627 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | Non-industry | None |
| Koskinen, 201228 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | Non-industry | None |
| Payne, 201615 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | Industry | Yes |
CEBM – Center of Evidence-Based Medicine